State of Wyoming’s Aligos Therapeutics ALGS Stock Holding History

State of Wyoming’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	-$1K	–	1775
2021 Q4	$1K	Hold	4	–	–	﹤0.01%	1793
2021 Q3	$1K	Sell	4 -1	-20%	-$396	﹤0.01%	1167
2021 Q2	$3K	Buy	5 +2	+67%	+$1.27K	﹤0.01%	1092
2021 Q1	$1K	Buy	+3	New	+$2K	﹤0.01%	480

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State of Wyoming's ALGS Position: Q1 2022 in Review

State of Wyoming sold out of Aligos Therapeutics (ALGS) in Q1 2022, closing a stake of 4 shares — an estimated $1K sold.

State of Wyoming first reported a position in ALGS in Q1 2021 and held it in 4 quarters. The position peaked at $3K in Q2 2021. 76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

State of Wyoming reported no remaining Aligos Therapeutics position as of Q1 2022 after selling out during the quarter.
State of Wyoming sold 4 Aligos Therapeutics shares in Q1 2022, an estimated $1K.
State of Wyoming first reported a position in Aligos Therapeutics in Q1 2021 and held it in 4 quarters.
State of Wyoming's Aligos Therapeutics position peaked at $3K in Q2 2021.
76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on State of Wyoming's 13F filing for Q1 2022, filed 13 May 2022.